We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-8.43%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$514M
AUM Growth
-$86.2M
(-14%)
Cap. Flow
-$11.8M
Cap. Flow
% of AUM
-2.3%
Top 10 Holdings %
Top 10 Hldgs %
22.06%
Holding
136
New
15
Increased
60
Reduced
35
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CONMED
CNMD
|
+$7.87M |
| 2 |
GoodRx Holdings
GDRX
|
+$6.71M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$6.43M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$5.7M |
| 5 |
Insulet
PODD
|
+$5.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Treace Medical Concepts
TMCI
|
+$9.71M |
| 2 |
Inspire Medical Systems
INSP
|
+$7.79M |
| 3 |
AGTI
Agiliti Inc
AGTI
|
+$7.74M |
| 4 |
Travere Therapeutics
TVTX
|
+$6.69M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$6.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.41% |
| 2 | Industrials | 2.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Sanofi
SNY
$103B
| $688K | 0.13% |
12,830
+1,934
| +18% | +$103K |
|
102
argenx
ARGX
$53.4B
| $603K | 0.12% |
1,227
+173
| +16% | +$84.6K |
|
|
ONC
103
BeOne Medicines Ltd
ONC
$32.8B
| $599K | 0.12% |
3,332
-2,468
| -43% | -$488K |
|
104
United Therapeutics
UTHR
$25.8B
| $591K | 0.12% |
2,615
+368
| +16% | +$84.8K |
|
105
Incyte
INCY
$24.2B
| $557K | 0.11% |
9,645
+1,467
| +18% | +$92.5K |
|
106
Jazz Pharmaceuticals
JAZZ
$15.9B
| $507K | 0.1% |
3,914
+580
| +17% | +$77.3K |
|
107
Royalty Pharma
RPRX
$25.9B
| $487K | 0.09% |
17,950
+2,588
| +17% | +$76.9K |
|
108
Neurocrine Biosciences
NBIX
$16.8B
| $454K | 0.09% |
4,035
+575
| +17% | +$60.5K |
|
109
Legend Biotech
LEGN
$3.59B
| $448K | 0.09% |
6,670
-1,330
| -17% | -$92.4K |
|
110
Ascendis Pharma A/S
ASND
$16B
| $397K | 0.08% |
4,241
+1,445
| +52% | +$135K |
|
111
BioNTech
BNTX
$22.9B
| $374K | 0.07% |
3,445
+116
| +3% | +$12.8K |
|
112
Roivant Sciences
ROIV
$24.5B
| $356K | 0.07% |
30,447
+5,020
| +20% | +$56.8K |
|
113
Veralto
VLTO
$23B
| $309K | 0.06% |
+3,658
| New | +$305K |
|
114
Dr. Reddy's Laboratories
RDY
$9.87B
| $301K | 0.06% |
22,500
-17,520
| -44% | -$237K |
|
|
HZNP
115
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $291K | 0.06% |
2,515
-5,384
| -68% | -$578K |
|
116
Medpace
MEDP
$16.1B
| $286K | 0.06% |
1,181
+55
| +5% | +$14.1K |
|
117
Exelixis
EXEL
$13.3B
| $273K | 0.05% |
+12,480
| New | +$261K |
|
|
APLS
118
DELISTED
Apellis Pharmaceuticals
APLS
| $199K | 0.04% |
5,220
-138,639
| -96% | -$6.09M |
|
|
FUSN
119
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $149K | 0.03% |
57,297
| – | – |
|
120
Arvinas
ARVN
$518M
| $138K | 0.03% |
7,010
+835
| +14% | +$20.5K |
|
121
Zai Lab
ZLAB
$2.06B
| $72.9K | 0.01% |
3,000
-5,000
| -63% | -$133K |
|
122
Summit Therapeutics
SMMT
$10.4B
| $37.4K | 0.01% |
20,000
-30,000
| -60% | -$57.2K |
|
123
Arcutis Biotherapeutics
ARQT
$3.36B
| $23.1K | ﹤0.01% |
4,357
-9,930
| -70% | -$84.4K |
|
124
Beam Therapeutics
BEAM
$2.63B
| – | – |
-63,500
| Closed | -$2.03M |
|
125
Bristol-Myers Squibb
BMY
$133B
| – | – |
-50,000
| Closed | -$3.2M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Sectoral Asset Management held 136 positions worth $514M, down 14% from $600M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Sectoral Asset Management's Q3 2023 filing shows 15 new, 60 increased, 35 reduced and 13 closed positions. Its largest new stake was GoodRx Holdings: 1,007,000 shares worth $5.67M. The largest sale was Treace Medical Concepts, an estimated $9.71M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials.
- Sectoral Asset Management's largest Q3 2023 buy was GoodRx Holdings: 1,007,000 shares worth $5.67M.
- Sectoral Asset Management added most to CONMED in Q3 2023, an estimated $7.87M increase.
- Sectoral Asset Management's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $6.63M.
- Sectoral Asset Management fully exited Treace Medical Concepts in Q3 2023, selling an estimated $9.71M.
- Sectoral Asset Management's ten largest holdings make up 22% of its $514M portfolio in Q3 2023.
- Sectoral Asset Management opened 15 new positions and closed 13 in Q3 2023.
- Sectoral Asset Management's portfolio value fell 14% quarter-over-quarter to $514M.
Based on Sectoral Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.